Literature DB >> 27342828

Low-Grade Salivary Gland Cancers: Treatment Outcomes, Extent of Surgery and Indications for Postoperative Adjuvant Radiation Therapy.

Jae-Keun Cho1, Byung-Woo Lim1, Eun-Hye Kim2, Young-Hyeh Ko3, Dongryul Oh4, Jae-Myoung Noh4, Yong Chan Ahn4, Kwan-Hyuck Baek5, Han-Sin Jeong6.   

Abstract

BACKGROUND: Histologic grade of tumor is one of the major prognostic predictors for patients with salivary gland cancer. Because of disease rarity, little is known about the optimal treatment modalities and outcomes in low-grade salivary gland cancers (LGSGC). We tried to identify prognostic factors, and the adequate treatment modalities and outcomes in pathologically confirmed LGSGC patients.
METHODS: We retrospectively extracted the clinical and pathology data from 179 LGSGC cases from 1995 to 2013. Pathological features, such as extraparenchymal extension, perineural/nerve invasion, lymphovascular invasion/tumor emboli, and resection margin status were redefined for each case. Risk factors for recurrence, extent of surgery, and the role of postoperative radiation therapy were analyzed.
RESULTS: Recurrence-free survival and overall survival were 89.6 and 96.6 % at 10 years, respectively. The presence of regional nodal metastasis and positive cancer cells at resection margin were significant unfavorable prognostic factors. Postoperative adjuvant radiation treatment significantly reduced recurrences, particularly in cases with pathology risk factors (perineural invasion, lymphovascular invasion, extraparenchymal extension, or cancer cells at the resection margin), node metastasis, and advanced T-stage tumors. Close surgical margin <5 mm was not a significant risk factor for recurrence, and less-than-total resection of the affected gland did not increase recurrence, if surgery could achieve a cancer cell-free surgical margin.
CONCLUSION: Postoperative radiation clearly benefitted patients with pathology risk factors, node metastasis, and advanced T stage in LGSGC. Meanwhile, the oncological outcomes are very good with surgery alone in cases of pT1-2N0 LGSGC without pathology risk factors.

Entities:  

Mesh:

Year:  2016        PMID: 27342828     DOI: 10.1245/s10434-016-5353-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

1.  Kaplan-Meier analysis of salivary gland tumors: prognosis and long-term survival.

Authors:  Yair Israel; Adi Rachmiel; Konstantin Gourevich; Rafael Nagler
Journal:  J Cancer Res Clin Oncol       Date:  2019-06-11       Impact factor: 4.553

2.  Close Margins and Adjuvant Radiotherapy in Acinic Cell Carcinoma of the Parotid Gland.

Authors:  Joseph Zenga; Anuurag S Parikh; Kevin S Emerick; Derrick T Lin; William C Faquin; Daniel G Deschler
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-11-01       Impact factor: 6.223

3.  Clinical value of adjuvant therapy on the prognosis of ductal carcinoma of the major salivary gland: a large-scale cohort study.

Authors:  Di Zhang; Lixi Li; Tingyu Wen; Fei Ma
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-08-29       Impact factor: 3.236

4.  Oncological outcomes of preoperatively unexpected malignant tumors of the parotid gland.

Authors:  Hanaro Park; Sungjun Han; Sung Joon Park; Young Ho Jung; Soon-Hyun Ahn; Woo-Jin Jeong
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-08-30       Impact factor: 2.503

5.  Pre-treatment metabolic tumor volume predicts tumor metastasis and progression in high-grade salivary gland carcinoma.

Authors:  Turki M Almuhaimid; Won Sub Lim; Jong-Lyel Roh; Jungsu S Oh; Jae Seung Kim; Soo-Jong Kim; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-06       Impact factor: 4.553

6.  Treatment outcomes in metastatic and localized high-grade salivary gland cancer: high chance of cure with surgery and post-operative radiation in T1-2 N0 high-grade salivary gland cancer.

Authors:  Jeon Yeob Jang; Nayeon Choi; Young-Hyeh Ko; Man Ki Chung; Young-Ik Son; Chung-Hwan Baek; Kwan-Hyuck Baek; Han-Sin Jeong
Journal:  BMC Cancer       Date:  2018-06-20       Impact factor: 4.430

7.  Incidence of postoperative facial weakness in parotid tumor surgery: a tumor subsite analysis of 794 parotidectomies.

Authors:  Hokyung Jin; Bo Young Kim; Heejung Kim; Eunkyu Lee; Woori Park; Sungyong Choi; Man Ki Chung; Young-Ik Son; Chung-Hwan Baek; Han-Sin Jeong
Journal:  BMC Surg       Date:  2019-12-26       Impact factor: 2.102

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.